- Home
- LGVN vs MBRX Comparison
LGVN vs MBRX Comparison
Compare LGVN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGVN | MBRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 12.8M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LGVN | MBRX |
|---|---|---|
| Price | $0.58 | $2.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.50 | ★ $105.50 |
| AVG Volume (30 Days) | 143.0K | ★ 193.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.49 | $0.25 |
| 52 Week High | $1.92 | $7.98 |
Technical Indicators
Market Signals| Indicator | LGVN | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.96 | 30.37 |
| Support Level | $0.52 | $4.03 |
| Resistance Level | $0.57 | $5.30 |
| Average True Range (ATR) | 0.03 | 0.35 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 96.44 | 0.92 |
Price Performance
Historical ComparisonAbout LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.